Evidence map›Paper›PMID 25930159›Full record

ArticleJournal of neurovirology2015

Human polyomavirus JC replication and non-coding control region analysis in multiple sclerosis patients under natalizumab treatment.

Valeria Pietropaolo, Anna Bellizzi, Elena Anzivino, Marco Iannetta, Maria Antonella Zingaropoli, Donatella Maria Rodio, Manuela Morreale, Simona Pontecorvo, Ada Francia, Vincenzo Vullo and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neurovirology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Valeria PietropaoloDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, P.le Aldo Moro, 5, 00185, Rome, Italy. valeria.pietropaolo@uniroma1.it.
Anna BellizziDepartment of Public Health and Infectious Diseases, Institute Pasteur, Cenci-Bolognetti Foundation, Sapienza University of Rome, Rome, Italy.
Elena AnzivinoDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, P.le Aldo Moro, 5, 00185, Rome, Italy.
Marco IannettaInstitut Cochin, Inserm U1016, Equipe Physiologie des cellules dendritiques, Paris, France.
Maria Antonella ZingaropoliDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, P.le Aldo Moro, 5, 00185, Rome, Italy.
Donatella Maria RodioDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, P.le Aldo Moro, 5, 00185, Rome, Italy.
Manuela MorrealeDepartment of Medico-Surgical Sciences and Biotechnologies, Section of Neurology, Sapienza University of Rome, Rome, Italy.
Simona PontecorvoIstituto di Ricerca e Cura a Carattere Scientifico-Neuromed, Pozzilli, Isernia, Italy.
Ada FranciaMultiple Sclerosis Center, Department of Neurology and Psychiatry, Sapienza University of Rome, Rome, Italy.
Vincenzo VulloDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, P.le Aldo Moro, 5, 00185, Rome, Italy.
Anna Teresa PalamaraDepartment of Public Health and Infectious Diseases, Institute Pasteur, Cenci-Bolognetti Foundation, Sapienza University of Rome, Rome, Italy.
Maria Rosa CiardiDepartment of Public Health and Infectious Diseases, Sapienza University of Rome, P.le Aldo Moro, 5, 00185, Rome, Italy.
Sapienza University of Rome · ITInserm · FRIstituto Neurologico Mediterraneo · ITIstituto Pasteur · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the last years, the treatment of multiple sclerosis (MS) patients with natalizumab has been associated with the occurrence of progressive multifocal leukoencephalopathy (PML) caused by human polyomavirus JC (JCV). Here, we have shown a significant correlation between patients with JC viruria and positive JC-specific antibody response and patients without JCV-specific antibodies after 1 year of natalizumab (p = 0.0006). Furthermore, JCV-specific quantitative PCR on urine and plasma samples, collected at the enrollment (t0) and every 4 months (t1, t2, t3) in the first year and at two time points (t4 and t5) in the second year of natalizumab treatment, indicated the prevalence of JC viremia rather than JC viruria only in the second year of treatment (p = 0.04). Moreover, the analysis of JCV non-coding control region (NCCR) sequences in peripheral blood mononuclear cells of patients with JC-specific antibodies after 12 natalizumab infusions (t3) revealed the presence of rearranged sequences, whereas the prevalence of genotypes 1A, 1B, and 4 was detected in these patients by VP1 sequence analysis. In summary, JC viruria evaluation seems to be useful to identify early those patients who do not already develop a humoral immune response against JCV. It may also be interesting to study the JCV NCCR rearrangements since they could give us new insights on the onset of neuro-invasive viral variants.

Indexed as

AdultAntibodies, ViralDNA, ViralEnzyme-Linked Immunosorbent AssayFemaleHumansImmunologic FactorsJC VirusMaleMultiple Sclerosis, Relapsing-RemittingNatalizumabReal-Time Polymerase Chain ReactionViral LoadViremiaVirus ReplicationAntibodies, ViralDNA, ViralImmunologic FactorsNatalizumabMultiple sclerosisNatalizumabNCCR sequencingPolyomavirus JCReal-time PCRSTRATIFY JCV®

Identifiers

PMID25930159
PMCPMC4628051
OpenAlexW2084464541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.